OptimizeRx Cuts FY26 Revenue Guidance to $87-$93M Despite Q3 EBITDA Beat
OPRX sits 62% above its 52-week low of $4.54 on elevated volume (3.3× avg).
Summary
OptimizeRx beat on Q3 EBITDA ($6.3M, 29% margin) but cut FY26 revenue guidance to $87-$93M as contracted revenue runs ~20% below last year; 2027 bookings are tracking ~20% ahead.
Key Events · Earnings and Guidance · OPRX
-
FY26 Revenue Guidance Cut
Full-year 2026 revenue guidance lowered to $87-$93 million; adjusted EBITDA guidance held at $21-$25 million. Contracted revenue for 2026 is tracking approximately 20% below the prior year.
-
Q3 EBITDA Beat, Revenue Down 17%
Q3 revenue of $21.6 million fell 17% from $26.1 million a year ago, but adjusted EBITDA rose to $6.3 million from $5.1 million — a 29% margin, up more than 900 basis points.
-
Retention Slides to 83%
Net revenue retention fell to 83% from 121%, driven by a small number of large accounts cutting spend; a previously displaced top-five client resumed spending in Q4 at below-historical levels.
-
Debt Paid Down to $10.4M
Repaid $9.3 million of debt principal since June 30, 2026, leaving $10.4 million outstanding; management flagged more share repurchase activity in Q4.
Analysis · OPRX · Trade & Services
The Q3 headline numbers beat: revenue of $21.6 million and adjusted EBITDA of $6.3 million, a 29% margin that is up more than 900 basis points year over year even as revenue fell 17%. The problem is the top line. Contracted revenue for 2026 is tracking roughly 20% below last year, so management cut full-year revenue guidance to $87-$93 million while holding adjusted EBITDA at $21-$25 million. Net revenue retention dropped to 83% from 121%, driven by a handful of large accounts rather than broad churn, and one previously displaced top-five client has only just resumed spending in Q4 off non-budgeted dollars. The bull case now rests on 2027: management says contracted revenue for next year is running about 20% ahead as the RFP season starts strong. Balance sheet work is real — $9.3 million of debt principal repaid since June 30 leaves $10.4 million outstanding, with more buyback activity flagged for Q4.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPRX was trading at $7.34 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $138.3M. The 52-week trading range was $4.54 to $16.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.